Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

MLA

Jabbour, E., et al. “Frequency and Clinical Significance of BCR-ABL Mutations in Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate.” Leukemia, vol. 20, no. 10, Oct. 2006, pp. 1767–73. EBSCOhost, https://doi.org/10.1038/sj.leu.2404318.

APA

Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O’Brien, S., Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., Rios, M. B., Verstovsek, S., & Cortes, J. (2006). Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia, 20(10), 1767–1773. https://doi.org/10.1038/sj.leu.2404318

Chicago

Jabbour, E, H Kantarjian, D Jones, M Talpaz, N Bekele, S O’Brien, X Zhou, et al. 2006. “Frequency and Clinical Significance of BCR-ABL Mutations in Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate.” Leukemia 20 (10): 1767–73. doi:10.1038/sj.leu.2404318.